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Carbohydrate (CHO) supplementation during prolonged exercise is widely acknowledged to 
blunt in vitro immunoendocrine responses but no study has investigated in vivo immunity.  
Purpose: To determine the effect of CHO supplementation during prolonged exercise on in 
vivo immune induction using experimental contact hypersensitivity (CHS) with the novel 
antigen Diphenylcyclopropenone (DPCP). 
Methods: In a double-blind design, 32 subjects were randomly assigned to 120 minutes of 
treadmill exercise at 60% ሶܸO2max with CHO (Ex-CHO) or placebo (Ex-PLA) 
supplementation. Responses were also compared to 16 resting control (CON) subjects from a 
previous study (for additional comparison with a resting non-exercise condition). 
Standardised diets (24 h pre-trial) and breakfasts (3.5 h pre-trial) were provided. Subjects 
received a primary DPCP exposure (sensitisation) 20 min after trial completion and exactly 
28 d later the strength of immune reactivity was quantified by magnitude of the cutaneous 
response (skin-fold thickness and erythema) to a low dose-series DPCP challenge. Stress 
hormones and leukocyte trafficking were also monitored.  
Results: CHO supplementation blunted the cortisol and leukocyte trafficking responses but 
there was no difference (P > 0.05) between Ex-CHO and Ex-PLA in the in vivo immune 
responses (e.g. both ~46% lower than CON for skin-fold response).   
Conclusions: CHO supplementation does not influence the decrease of in vivo immunity seen 
after prolonged exercise. The effects with more stressful (or fasted) exercise remain to be 
determined. However, there appears to be no benefit under the conditions of the present 
study, which have practical relevance to what many athletes do in training or competition.  
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It is widely reported that athletes engaged in regular prolonged and/or strenuous exercise, and 
those in physically demanding occupations (e.g. soldiers), have a higher than normal 
incidence of upper respiratory tract illness (URTI) symptoms, which may be related to an 
exercise-induced impairment of immune function (immunodepression) [1, 2]. It has 
previously been suggested that the primary mechanisms contributing to such exercise-
induced immunodepression include the exercise-induced stress responses (i.e. increased 
stress hormones, in particular cortisol; cytokines; inflammatory responses); and the 
redistribution of leukocytes and their subsets (e.g. [3±5]).  Many nutritional interventions 
have been investigated as potential countermeasures to exercise-induced immunodepression 
and acute supplementation with carbohydrate (CHO) is often cited as the most efficacious [6±
8]. Supplementation with CHO has been consistently shown to blunt many of the exercise-
induced immune and endocrine perturbations (e.g. increased cortisol, cytokine, and leukocyte 
redistribution responses; decreased neutrophil degranulation and oxidative burst functions, 
lymphocyte proliferation and functions, natural killer cell function [4±12]) although it is not 
clear how this may influence infection risk [8, 12]. Such in vitro markers provide useful 
insight into the impact of nutritional interventions but alone they are considered to lack 
clinical relevance as the extent to which changes in these in vitro or ex vivo measures are 
related to increased infection risk is unclear [13, 14]. To date, the vast majority of the 
supportive evidence for CHO supplementation is based on in vitro measures (e.g. [4, 5, 9±
11]), with little evidence on URTI [15] and no evidence on in vivo immunity. In one study, 
Nieman et al. [15] studied approximately 100 marathon runners randomly allocated to receive 
placebo or CHO beverages (providing ~60 g per hour) during a competitive marathon race. 
Carbohydrate supplementation was associated with higher post-race plasma glucose and 
insulin concentrations, and lower post-race cortisol and growth hormone concentrations. 
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However, they observed little benefit of CHO, compared to placebo, on the response of a 
range of salivary immune parameters (including IgA secretion rate, IgA relative to protein, 
and absolute IgA concentration, which actually decreased less in the placebo group). Nieman 
et al. [15] were also able to obtain URTI data for the 15-day post-race period from 93 of the 
participants, and found no difference in URTI incidence between the CHO and placebo 
groups. However, the validity of using self-reported URTI has been questioned [14].  
 
The normal immune response (and hence host defence and protection) involves a complex 
and co-ordinated network of molecules, cells and tissues working in synergy. Hence, in vivo 
immune markers are considered particularly valuable [13, 14]. Cutaneous measures of in vivo 
immunity, such as delayed type hypersensitivity responses to intradermal injection of 
antigens, or contact hypersensitivity (CHS) responses to epicutaneous application of antigens, 
represent challenge-type measures, which have recently been suggested to be most useful in 
immunonutrition studies, when considering biological relevance, sensitivity and feasibility 
[14]. The clinical relevance of examining cutaneous in vivo immunity is supported by studies 
that have used such measures to monitor immune-competence in HIV-infected patients [16], 
and studies showing that the magnitude of the responses relate to URTI risk in children [17] 
or predict mortality in patients with surgical infections [18]. It has been previously 
demonstrated that the CHS response, using the novel antigen diphenylcyclopropenone 
(DPCP), is significantly reduced after 2 hours of treadmill running. This includes both the 
induction of immunity (-53%), in participants with no prior exposure, and the elicitation of 
immunity (-19%), in participants with well-established immune memory, to DPCP [19]. We 
have now demonstrated this as a controllable, reproducible, sensitive, and valid in vivo 
marker of exercise-induced immunodepression [19, 20]. Furthermore, we have recently 
demonstrated no effect of WKHVDPHH[HUFLVHKRIWUHDGPLOOUXQQLQJRQWKHVNLQ¶VUHVSRQVH
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to the irritant croton oil [20], providing further support for the suggestion that the observed 
decrease in in vivo immune induction to DPCP is an antigen-specific, T cell mediated, 
response.  
  
Challenging the skin using novel antigens permits the investigation of the influence of 
stressors on in vivo immune induction and allows rigorous control of both the dose and 
timing of sensitisation [19]. We are not aware of any previous study that has utilised such an 
in vivo marker to determine the effects of nutritional interventions such as CHO 
supplementation on exercise-induced immunodepression. To date, the most supportive 
evidence for a nutritional strategy to limit the exercise-induced immune perturbations is for 
CHO supplementation, but no study has investigated in vivo immunity. Therefore, the aim of 
the present study was to determine the effects of acute CHO ingestion, before, during and 
after prolonged exercise, on induction of the CHS response to DPCP.  We hypothesised that 




This study was conducted according to the guidelines laid down in the Declaration of 
Helsinki (2008, including 2013 amendments) and all procedures were approved by the local 
University Research Ethics Committee. Written informed consent was obtained from all 
subjects. Subjects also completed a pre-exercise screening questionnaire (Physical Activity 





Thirty two men were included in this study (age 28.8 ± 8.1 years, body mass 76.2 ± 10.1 kg, 
maximal oxygen uptake, ሶܸO2max, 58.3 ± 6.4 mL.min-1.kg-1; means ± standard deviation for 
all 32 subjects; values for individual groups are summarised in Table 1). All participants were 
healthy, non-smoking, and recreationally active (familiar with running) with no previous 
history of exposure to DPCP. Subjects were excluded if they were taking any medication or 
dietary supplements, had a history of atopy or any other immune-related or inflammatory 
dermatological or relevant medical conditions. Other exclusion criteria included current (or 
within two weeks of recovery from) infection prior to the study, having any vaccinations in 
the 2 months preceding the study, and donating blood in the four weeks before the study.   
Participants were asked to abstain from strenuous exercise in the 24 hours before and 48 
hours following each trial (exercise/sensitisation and elicitations).  Participants were asked to 
abstain from the consumption of alcohol or caffeinated drinks 48 hours ahead of each trial.  
 
Study design 
In the current study, 32 subjects were randomly assigned to either 120 minutes of treadmill 
exercise at 60% ሶܸO2max with CHO supplementation (Ex-CHO, n = 16), or 120 minutes of 
treadmill exercise at 60% ሶܸO2max with placebo (Ex-PLA, n = 16). As a point of reference 
for the normal response in rested individuals, we also statistically compared the Ex-CHO and 
Ex-PLA groups¶ in vivo immune induction responses to the control group (CON, n = 16, who 
completed 120 minutes of seated rest) from Diment et al. [20]. Subjects were allocated 
randomly into either the Ex-CHO or Ex-PLA groups after being matched for physical 
characteristics, speed at gas exchange threshold (GET) and speed at ሶܸO2max (and hence 
relative exercise intensity in the main trials). The PLA and CHO conditions were 
administered in a double-blind manner. All subjects undertook two preliminary tests 




Determination of maximal oxygen uptake ( ሶܸO2max) ሶܸO2max was determined by an incremental exercise test on a motorised treadmill 
(H/P/Cosmos Sport and Medical, Nussdorf-Traunstein, Germany) in accordance with the 
methods of Diment et al. [20].  The test began at a treadmill speed of 5 km·h-1, with a 1% 
incline, for 3 minutes.  The speed was then increased by 1 km·h-1 every minute until a speed 
of 18 km·h-1 was attained and then further increases were achieved by increasing the gradient 
by 1% every minute until volitional exhaustion.  Heart rate was recorded throughout using a 
short range telemetry heart rate monitor (Polar 810i, Polar Electro, Kempele, Finland); rating 
of perceived exertion (RPE) was recorded at the end of each minute [21]; breath-by-breath 
gas exchange was recorded using an online system (Cortex Metalyser 3B, Cortex Biophysik, 
GmbH, Leipzig, Germany) throughout the duration of the test.  The gas analysis system was 
calibrated prior to use according to the manufacturer's guidelines using a calibration gas of 
known composition and a three-litre syringe (Hans Rudolf Inc, Kansas, USA). ሶܸO2max was 
recorded as the highest average ሶܸO2 over any 30 second period of the test. The speed required 
to elicit 60% ሶܸO2max was estimated from the linear part of the ሶܸO2 - speed relationship, and 
later verified in the familiarisation trial. The intensity at 60% ሶܸO2max was also expressed as a 
percentage of the difference between GET and ሶܸO2PD[ǻLQDFFRUGDQFHZLWKWKH
methods of Lansley et al. [22], to verify that the relative intensity (and hence relative 
physiological stress) were equal between exercise groups. 
 
Familiarisation  
Subjects completed a familiarisation session one week prior to the main trial.  Participants 
completed a warm-up for 5 minutes at 5 km·h-1 and 1% gradient on the same treadmill used 
for the ሶܸO2max test. This was immediately followed by a 60 minute run at a speed equivalent 
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to 60% ሶܸO2max to familiarise subjects to the main trial exercise procedures and confirm 
accuracy of the calculated speed (to elicit 60% ሶܸO2max). Minor speed adjustments were made 
during the first 15 min if necessary to attain the target 60% ሶܸO2max. Subjects were provided 
with 5 ml·kg-1 body mass water bolus 20 min before exercise commencement and on trial 
completion and 2 ml·kg-1 was provided every 15 min during the trial to familiarise subjects 
with the fluid provision schedule to be followed in the main trials. Heart rate and RPE were 
recorded every 5 min.  
 
Main trials 
Standardisation and pre-exercise preparation of subjects: Dietary intake was controlled 
during the 24 h before the main experimental trial by providing subjects with 35 mL·kg-1·d-1 
water and food from a standard food list to meet their estimated daily energy requirement 
(11.4 ± 1.5 MJ·d-1, which was comprised of 15%, 60%, and 25% of energy from protein, 
CHO and fat respectively, and was equivalent to ~1.3, 5.4 and 1.0 g·kg-1 body mass, 
respectively). They were also provided with a standard breakfast at 07:30 on the morning of 
the main trial to provide ~0.03 MJ·kg-1 (equivalent to 2.4 ± 0.3 MJ, comprised of ~0.2, 1.0 
and 0.2 g·kg-1 of protein, CHO and fat, respectively). To further standardise dietary intake 
subjects were also provided with lunch after the final blood sample collection (see timings 
below), to provide ~0.02 MJ·kg-1 (equivalent to 1.6 ± 0.2 MJ, comprised of ~0.2, 1.0 and 0.2 
g·kg-1 of protein, CHO and fat, respectively).  
 
Experimental procedures  
Subjects were provided with breakfast (as detailed above) at 07:30 before beginning the 120 
min exercise (Ex-CHO and Ex-PLA) at 11:00. They were also provided with a quantity of 
water for the 3 h period between 07:30 and 10:30 proportional to their daily requirement but 
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pro rata for this period (based on their calculated requirement for the prior 24 h, equating to 
approximately 6.6 mL·kg-1). During this period they were required to be restful but were 
allowed to undertake light activities such as reading or using a computer. They were then 
required to sit for 10 min with minimal movement before resting blood samples were 
collected. Subjects received a bolus of 5 mL·kg-1 of their respective drink (CHO or PLA) 20 
min before and immediately after exercise and 2 mL·kg-1 every 15 min during exercise. 
Exercise commenced at 11:00 and immediately after the trial, post-exercise blood samples 
were collected, then subjects showered and returned to the laboratory within 15 minutes of 
completion for patch application at exactly 20 min post-exercise (i.e. 13:20) to sensitise 
subjects to DPCP (details below). A final blood sample was also obtained 1 h post-exercise. 
During exercise, expired gas was analysed during minutes 10, 20, 40, 50, 70, 80, 100, and 
110 of exercise using the Douglas bag method. Gas was analysed using a gas analyser 
(Servomex, Crowborough, UK) and a dry gas meter (Harvard Apparatus, Edenbridge, UK).  
7KHJDVDQDO\VHUZDVFDOLEUDWHGSULRUWRXVHDFFRUGLQJWRWKHPDQXIDFWXUHU¶VJXLGHOLQHVXVLQJ
calibration gasses of known composition. Heart rate and RPE were recorded every 15 min 
during exercise. Elicitation was then performed (details below) exactly 28 days after this trial.  
 
Drink composition: The CHO drink was prepared with a lemon flavoured CHO-based sports 
GULQNSRZGHU*R(QHUJ\6FLHQFHLQ6SRUW1HOVRQ8.DFFRUGLQJWKHPDQXIDFWXUHU¶V
instructions (to give a CHO concentration of 10% w/v). The placebo was CHO-free and 
prepared from sugar-free, artificially sweetened lemon flavoured drink concentrate (Tesco, 
Dundee, UK) diluted 4 parts water to 1 part concentrate. The concentrations were determined 
so that drinks were taste matched as closely as possible. Even though this may not be 
necessary with the between groups design employed here, we taste matched drinks as closely 
as possible to avoid potential loss of blinding (i.e. subjects discussing their drinks outside of 
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the study/laboratory). A laboratory technician, independent of the study, was responsible for 
the drink preparation to maintain double-blind procedures. The drinking schedule provided 
approximately 60 g CHO per hour during exercise (in addition to the pre- and post-exercise 
boluses of ~40 g each) for an average sized subject.   
 
Induction of contact sensitivity (sensitisation) 
Subjects were sensitized to DPCP at 13:20, exactly 20 min post-exercise (to ensure cutaneous 
blood flow had returned to baseline) in accordance with the methods of Harper Smith et al. 
[19] and Diment et al. [20]. Sensitisation was achieved by the application of an occluded 
patch, constituting a 12 mm aluminium Finn chamber (Epitest Oy, Tuusula, Finland) on 
scanpor hypoallergenic tape containing an 11 mm filter paper disc. The disc was soaked in 
ȝORI'3&3LQDFHWRQHDQGDOORZHGWRGU\IRUPLQXWHVEHIRUHEHLQJDSSOLHGWR




The magnitude of in vivo immune responsiveness was quantified by measuring the responses 
elicited by secondary exposure to the same antigen, also in accordance with the methods of 
Harper Smith et al. [19] and Diment et al. [20]. That is, exactly 28 days after the initial 
sensitisation to DPCP, all subjects received a challenge with a low concentration dose-series 
of DPCP on individual patches, each comprising an 8 mm aluminium Finn chamber on 
scanpor hypoallergenic tape containing a 7 mm filter paper disc. Patches were applied to the 
LQQHUDVSHFWRIWKHXSSHUDUPLQWKHIROORZLQJGRVHVRI'3&3SHUSDWFKȝJÂFP-2; 1.98 
ȝJÂFP-2ȝJÂFP-2ȝJÂFP-2ȝJÂFP-2 and an additional acetone only control 
patch for background subtraction. Patches were applied in randomly allocated order at the 
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local site in order to minimize any anatomical variability in responses. This pattern was 
matched between subjects in each of the groups however (i.e. for every allocation pattern 
used in one group there was an equivalent identical pattern used in the other). Elicitation 
patches were removed after precisely 6 h and the strength of immune reactivity was assessed 
as cutaneous responses at 48 h post-application.  This method allows the magnitude of in vivo 
immune responsiveness to be quantified (e.g. establishment of immune memory in response 
to the sensitisation induced during the acute post-exercise period).  
 
Assessment of cutaneous responses  
Skin oedema (inflammatory swelling) is considered the key measure of CHS elicitation 
responses [19]. This was assessed as mean skin-fold thickness from triplicate measurements 
at each elicitation site using modified spring-loaded skin callipers (Harpenden Skin-fold 
Calliper, British Indicators, England), to the nearest 0.1 mm (measuring skin-fold only: i.e. 
no subcutaneous fat) as described previously [19, 20]. Skin erythema was determined from 
triplicate measurement at each patch site using an erythema meter (ColorMeter DSM11, 
Cortex Technology, Hadsund, Denmark) as previously described [19, 20]. Mean background 
values were determined from triplicate measurements at the acetone only control patch site 
for thickness and erythema. In order to determine the increase in thickness and erythema in 
response to DPCP, the value from the acetone only control site was subtracted from each 
patch site value. The values for increase in skin-fold thickness, and erythema over all the 
doses were summed to give a representative measure of the overall reactivity of each subject 
to DPCP [19, 20]. The dose-response curve was also used to conduct sensitivity analyses (i.e. 
identify the minimal dose required to elicit a positive response, for the skin-fold measure) in 





Blood samples were obtained by venepuncture, with minimal stasis, from an antecubital vein 
and collected into vacutainer (Becton Dickinson, Oxford, UK) tubes (containing lithium 
heparin or K3EDTA). All blood samples were obtained while subjects were in the seated 
position. Subjects were asked to sit without changes of posture and minimal movement for 10 
min before all blood samples were drawn, except the Post-Ex sample, which was drawn as 
soon as possible after completing the exercise (within 5 min). A small aliquot was taken from 
the K3EDTA tube for haematological analysis and then all samples were centrifuged 
immediately at 1500 × g for 10 minutes at 4°C.  Aliquots of plasma were stored at -80°C for 
later analysis.   
 
Analytical methods 
Haematological analysis was performed on the K3EDTA treated blood aliquot using 
automated haematology analysers (Gen-S, Beckman Coulter, High Wycombe, UK; ABX 
Pentra 60C+, Horiba Medical, France).   
 
*** Please insert table 1 near here *** 
 
Glucose concentration was determined in heparinised plasma using an automated analyser 
(YSI 2300 Stat Plus, Yellow Springs, OH, USA).  Plasma cortisol concentration in 
heparinised plasma was determined using a commercially available enzyme linked 
immunosorbent assay (ELISA) kit (DRG, Germany; Biomercia, Ca, USA). Plasma 
epinephrine and norepinephrine concentrations in K3EDTA plasma were determined using a 
commercially available CatCombi ELISA (IBL International, Hamburg, Germany). All 





Statistical analyses were carried out using SPSS (IBM SPSS Statistics for Windows, Version 
21.0, Armonk, NY: IBM Corp.). Values were compared between groups using 1-way 
independent ANOVA or t-tests, or for variables with repeated measures, 2-way mixed 
ANOVA. If data were not normally distributed they were first normalised with log 
transformation using the natural log WUDLQLQJKRXUVǻ# ሶܸO2max, neutrophil count, 
neutrophil-to-lymphocyte ratio, adrenaline, noradrenaline, summed skin-fold responses), or 
1/x2 (total leukocyte count) transformations. Post hoc Holm-Bonferroni corrected paired (for 
within groups comparisons) or independent (for between groups) t-tests were applied where 
appropriate. All results are presented as mean r standard deviation unless otherwise stated. 
 
Results 
Participants were well matched for physical characteristics with no significant differences for 
any of the physical parameters except ሶܸO2max, (Table 1). However, exercise responses were 
similar between groups (Table 2) and, importantly, there was no difference in the trial relative 
exercise intensity (this holds true whether expressing relative intensity as % ሶܸO2max during 
WKHWULDORUǻ, whereby exercise intensity is expressed relative to the individual GET and ሶܸO2max).  
 
*** Please insert Table 2 near here *** 
 
CHS responses to DPCP 
Oedema responses: For the skin-fold responses, 1-way independent ANOVA (including 
comparison to the CON group from [20]) showed a main effect of group (F2,45 = 3.370, P = 
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0.043). There was no difference between the Ex-CHO or Ex-PLA groups (post hoc analysis: 
between Ex-PLA and Ex-CHO, P = 0.460; mean difference 1.04 mm, 95% confidence 
intervals 0.45 to 2.41 mm) but there was a difference between the CON and Ex-PLA (P = 
0.026, mean difference 2.29 mm, 95% confidence intervals 1.11 to 4.71 mm) and between the 
CON and Ex-CHO (P = 0.036, mean difference 2.38 mm, 95% confidence intervals 1.13 to 
5.02 mm, see Figure 1). The exercise trials were both ~46% lower (P < 0.05) than the CON 
responses reported by Diment et al. [20]. Sensitivity analysis revealed the average threshold 
GRVHIRUDUHVSRQVHWR'3&3ZDVȝJ·cm2 for the CON group but a dose ~3-fold higher 
was required (2.81-fold for PLA and 2.88-fold for CHO) in order to elicit a positive response 
in the exercise groups. 
 
*** Please insert Figure 1 near here *** 
 
Erythema responses: One-way independent ANOVA (including comparison to the CON 
group from [20]) showed a main effect of group (F2,45 = 3.219, P = 0.049). There was no 
difference between the Ex-CHO or Ex-PLA groups (post hoc analysis: between Ex-PLA and 
Ex-CHO, P = 0.290, mean difference 4.22 AU, 95% confidence intervals -11.16 to 19.60 
AU), no difference between CON and Ex-PLA (P = 0.070, mean difference 14.29 AU, 95% 
confidence intervals -1.25 to 29.83 AU) and a significant difference between CON and Ex-
CHO (P = 0.036, mean difference 18.51 AU, 95% confidence intervals 2.6 to 34.41 AU, see 
Figure 2).  
 
*** Please insert Figure 2 near here *** 
 
Blood leukocyte counts 
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It was not possible to obtain a blood sample at every time point for some individuals (for 
example, if a post-exercise sample could not be obtained within 5 min it was abandoned to 
avoid delays in patch application, as the CHS responses were of primary importance). For 
this reason the sample sizes for these measures were n = 12 for the Ex-PLA group and n = 11 
for the Ex-CHO group. Significant main effects for ANOVA comparisons (group, time and 
group × time) were evident for most leukocyte parameters (total leukocyte count, neutrophil 
count, lymphocyte count, and neutrophil-to-lymphocyte ratio) with the exception of no 
significant group effects for total leukocyte count, lymphocyte count, and neutrophil-to-
lymphocyte ratio (detailed in Table 3). Post hoc analysis on the time effect (in each group 
separately, owing to the observed interactions) showed that significant leukocyte trafficking 
was evident in Ex-PLA at Post-Ex (P < 0.001) and 1 h Post-Ex (P < 0.001) and Ex-CHO at 
Post-Ex (P = 0.002) and 1 h Post-Ex (P < 0.001) but counts were significantly lower at Post-
Ex (P = 0.009) and 1 h Post-Ex (P = 0.001) in the Ex-CHO compared to Ex-PLA group (see 
Table 3). Significant neutrophil trafficking was evident in Ex-PLA at Post-Ex (P < 0.001) and 
1 h Post-Ex (P < 0.001) and Ex-CHO at Post-Ex (P < 0.001) and 1 h Post-Ex (P = 0.004) but 
counts were significantly lower at Post-Ex (P = 0.003) and 1 h Post-Ex (P < 0.001) in the Ex-
CHO compared to Ex-PLA group (see Table 3). A significant time effect was evident for 
lymphocyte count (trafficking) and a significant group × time interaction indicates that this 
pattern differs between groups. Post hoc comparison did not reveal any between group 
differences at any of the time points (Table 3) but there was a significant increase in Ex-PLA 
at Post-Ex (P = 0.006) but no change over time in the Ex-CHO group (P = 0.262). The 
neutrophil-to-lymphocyte ratio increased significantly in Ex-PLA at Post-Ex (P < 0.001) and 
1 h Post-Ex (P < 0.001) and Ex-CHO at Post-Ex (P = 0.028) and 1 h Post-Ex (P = 0.020) but 
neutrophil-to-lymphocyte was significantly lower at 1 h Post-Ex (P = 0.002) in the Ex-CHO 




*** Please insert Table 3 near here *** 
 
Stress hormones and glucose 
For stress hormones and glucose n = 12 for the Ex-PLA group and n = 11 for the Ex-CHO 
group. Significant main effects of group, time and group × time interaction were evident for 
plasma glucose, which was significantly higher at Post-Ex and 1 h Post-Ex in the Ex-CHO 
group compared to Ex-PLA (Table 4). Post hoc analysis on the time effect (in each group 
separately, owing to the observed interaction) revealed a significant decrease below Pre-Ex 
concentration at 1 h Post-Ex in the Ex-PLA group (P = 0.032) and a significant increase at 
Post-Ex (P < 0.001) and 1 h Post-Ex (P = 0.011) in the Ex-CHO group.  
 
Significant main effects of time, and group × time interaction were evident for plasma 
cortisol, which was significantly lower Post-Ex and 1 h Post-Ex in the Ex-CHO compared to 
the Ex-PLA group (Table 4). Post hoc analysis on the time effect (in each group separately, 
owing to the observed interaction) revealed no differences in the Ex-PLA group (P > 0.05) 
and a significant decrease at Post-Ex (P < 0.001) and 1 h Post-Ex (P < 0.001) in the Ex-CHO 
group (in line with the normal expected diurnal pattern). 
 
Significant main effects of time were evident for both adrenaline and noradrenaline (i.e. an 
exercise response) but there were no differences between Ex-CHO and Ex-PLA groups 
(interactions P > 0.05, Table 4). Post hoc analysis on the time effect (both groups considered 
together, owing to the lack of interaction) revealed a significant increase in plasma adrenaline 




*** Please insert table 4 near here *** 
 
Discussion 
The aim of the present study was to determine the effects of acute CHO ingestion, before, 
during, and after prolonged exercise, on the in vivo immune response (CHS) to the novel 
contact antigen DPCP.  The main findings were that despite CHO ingestion blunting the 
cortisol and leukocyte trafficking responses to prolonged treadmill running, there was no 
effect on in vivo immune response to DPCP. When comparing to the resting CON group from 
Diment et al. [20] in vivo immune induction (oedema assessed by skin-fold thickness) in the 
present study was significantly lower (-46%). Sensitivity analysis also revealed that the 
threshold dose for a response to DPCP was ~3-fold higher (2.81-fold for PLA and 2.88-fold 
for CHO) in order to elicit a positive response. Previous research has consistently 
demonstrated that prolonged exercise (2 h treadmill running at 60% ሶܸO2max) reduces in vivo 
immune induction as assessed by this method [19, 20]. The exercise groups in the present 
study exhibited similar responses to the exercise groups in both of these previous studies [19, 
20]. This, in conjunction with direct statistical comparison with the CON group of Diment et 
al. [20], shows that the prolonged exercise in the present study reduced in vivo immune 
induction. However, the present study suggests that this decrease is not altered by acute CHO 
supplementation.  
 
Challenging the skin using novel antigens permits the investigation of the influence of 
stressors on in vivo immune induction and allows rigorous control of both the dose and 
timing of sensitisation [19]. However, we are not aware of any previous study that has 
utilised in vivo immune induction of CHS to determine the effects of nutritional interventions 
on exercise-induced immunodepression. Despite the large body of research showing CHO 
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supplementation to blunt the prolonged exercise-induced responses for a wide array of 
immune markers (e.g. [4, 5, 9±11]), there is a lack of evidence on the effects of CHO 
supplementation on in vivo immune function and/or clinically relevant outcomes. The 
findings of the present study, that CHO supplementation did not benefit in vivo immunity 
post-exercise, is broadly in line with Nieman et al. [15] who compared placebo or CHO 
beverage-supplemented runners during a competitive marathon race. In that study Nieman et 
al. [15] observed CHO supplementation (approximately 60 g per hour) to be associated with 
higher post-race plasma glucose and insulin concentrations, and lower post-race cortisol and 
growth hormone concentrations. However, there was no difference between the CHO and 
placebo groups in salivary IgA responses (considered high value markers in relation to URTI 
risk, [14]) or URTI incidence in the 15-day post-race period.  However, as this was a field-
based study in which subjects were racing, it is possible that performance would have 
differed (relative to each individual¶s current potential performance or fitness) or that the 
CHO could have ergogenic effects meaning it is difficult to confirm whether subjects were 
exposed to the same relative stress (both physiological and psychological) in each group. 
Hence, in the present study we investigated in vivo immune function using the CHS 
µFKDOOHQJH-WHVW¶ZLWKotherwise standardised diet and exercise conditions. Given the outcomes 
previously reported for immune markers, with CHO supplementation, we hypothesised that 
CHO would protect against the exercise-induced decrease of in vivo immunity. However, 
contrary to our original hypothesis, and despite significant blunting of the leukocyte (and 
leukocyte subset) trafficking and cortisol responses, there was no difference between the Ex-
CHO and Ex-PLA groups in in vivo immune function. Therefore, these results suggest that 
CHO supplementation does not protect against prolonged exercise-induced 
immunodepression when assessed using an in vivo immune marker, which we [19, 20] and 




For consistency between groups, we were careful to control diet and CHO intake before (i.e. 
on the day before and the morning of) the main trials and during the period of sensitisation so 
that the only difference between groups was CHO content of drinks consumed acutely before, 
during, and after the prolonged exercise. Many previous studies required subjects to exercise 
following an overnight fast and it is possible, therefore, that immune alterations would be 
more pronounced in these circumstances. We chose to provide a standard breakfast in order 
to replicate what many athletes often do in training and competition and, as such, our results 
have practical relevance to such athletes. This presents the possibility that CHO 
supplementation during exercise would be more beneficial if exercise was commenced in the 
fasted state, which may be used by some athletes in certain sessions (e.g. see reference [23] 
for a recent review on the practice of training with low CHO availability). However, 
consuming a CHO-containing beverage would be counterproductive to any athlete wishing to 
SUDFWLFHWKLVµWUDLQORZ¶PHWKRGDVLWZRXOGQHJDWHWKHIXQGDPHQWDOSULQFLSOHRIWUDLQLQJ
low). As such, our approach for determining the effect of acute CHO ingestion on the in vivo 
immune responses to prolonged exercise in the fed state seems the most valid and of practical 
relevance for athletes. In the current study, the fact that we still observed notable differences, 
between the Ex-CHO and Ex-PLA conditions, in plasma glucose, leukocytosis and a number 
of stress markers typically associated with exercise and/or CHO ingestion demonstrates that 
there was a meaningful difference between the Ex-CHO and Ex-PLA groups in terms of the 
stress response to exercise. We suggest, therefore, that the lack of difference between CHO 
and PLA conditions in the present study cannot be explained by the fact that subjects were 
fed a standard breakfast 3.5 h before the exercise trials. These findings are in line with 
previous studies showing that in vivo immune responses to DPCP are unrelated to stress 
hormone responses induced by exercise [20] or altitude [24]. Taken together, this offers a 
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feasible explanation for the lack of effect of CHO supplementation on DPCP responses, 
despite a blunting of many of the stress response markers typically proposed to be responsible 
for the immunodepressive effects associated with prolonged and strenous exercise.  Induction 
of CHS is dependent upon dendritic cell activation at the skin, dendritic cell migration from 
the skin to the regional lymph nodes and subsequent clonal expansion of specific T cells [25], 
and represents an in vivo measure of the whole integrated immune response. As we have 
demonstrated no effect of CHO supplementaiton on this in vivo immune measure, and since 
the stress hormone (particularly cortisol) response does not seem to be implicated [20], it is 
now necessary to further explore the mechanisms responsible for the exercise-induced 
decrease in in vivo immunity and suitable nutritional countermeasures. 
 
Limitations 
The results for erythema responses were generally in line with the oedema responses but 
when comparing to the CON data of Diment et al. [20] the summed response was 
significantly lower in the Ex-CHO condition (~41%) but there was only a trend for lower 
responses in the Ex-PLA group (~32%). Importantly, however, there was no difference 
between the Ex-PLA and Ex-CHO groups (if anything the response was lower in the CHO 
group). Since the use of erythema may suffer from interference at sites of a strong response, 
where yellow vesicles can interfere with the erythema readings [19, 20] the oedema results of 
this study should be taken as the primary indication of CHS. Importantly, even if using the 
erythema data, the overall conclusion would remain the same, that acute CHO ingestion 
before, during and after prolonged exercise does not benefit in vivo immunity. 
 
We recognise a limitation of the current study is that we did not concurrently measure any of 
the previously reported functional in vitro markers (e.g. neutrophil function, lymphocyte 
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proliferation, stimulated cytokine production) for comparison with in vivo responses. 
However, it is well-established and consistently reported that CHO supplemention blunts 
many of the prolonged-exercise-induced alterations in in vitro immune measure (e.g. [4, 5, 9±
11]). OXUFXUUHQWUHVXOWVGRQRWVXJJHVWWKDWVXEMHFWV¶UHVSRQVHVZHUHDQ\GLIIHUHQWIURP
those typically observed in such studies: we observed the typical exercise-induced increases 
of stress hormones and leukocyte trafficking which were blunted by CHO ingestion.  This 
study therefore supports the recent findings of Diment et al. [20] that the induction of 
immune memory is decreased by prolonged exercise but the circulating stress hormone 
responses do not appear to be responsible. This also agrees with Oliver et al. [24] who 
showed that reduced CHS responses after ascent to altidude were not related to the stress 
hormone response. The current study does support the previously reported effects of CHO 
supplementation on blunting of stress and leukocytosis responses to prolonged exercise (e.g. 
[4, 5, 9, 11]) but it does not support the use of CHO as an acute nutritional intervention of 
benefit to in vivo immunity.  This also seems to support the notion that in vitro measures do 
not sufficiently capture the whole integrated immune response and as such, are not 
representative of in vivo host defence.  As a result, it would be beneficial for future studies to 
include in vivo measures in order to test the utility of proposed nutritional countermeasures 
for immune impairment after prolonged exercise.  
 
We also recognise that the CHS response to DPCP is benign, and the clinical significance of 
the response, with specific regard to URTI in athletes, has not yet been established [20]. 
Nevertheless, the clinical relevance of in vivo cutaneous immune measures has been 
demonstrated in other contexts e.g. relationships with the progression of immunodeficiency; 
progression of acute to persistent diarrhoea; and URTI risk in children [17, 26±28]. In the 
current study, we have used the CHS response as a marker of in vivo immune function but do 
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acknowledge that future research must confirm the relationship between this and illness (e.g. 
URTI) risk in athletes.  
 
Conclusion 
Based on the results of this study, acute CHO ingestion before, during and after exercise does 
not blunt the decrease of in vivo immunity observed following 2 h of moderate exercise in the 
fed state (exercise commencing 3.5 h after breakfast). It remains to be determined, however, 
whether there would be any benefit with exercise that places a greater stress on CHO 
availability (e.g. longer duration and/or in the fasted state), or during periods of intensified 
training. However, we propose that the current design is relevant to what many athletes 
actually do in training and competition althouh the effects of more chronic CHO 
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Table 2. Exercise responses during main trial 
 PLA-Ex CHO-Ex t-test P value 
ǻ# ሶܸO2max 39.6 (28.7)% 38.8 (36.4)% 0.622 
 
 
Mean % ሶܸO2max 59.6 (4.9)% 58.2 (4.7)% 0.432 
 
 
HR (bpm) 140 (15) 138 (12) 0.686 
 
RPE 11 (2) 11 (2) 0.182 










Table 1. Subject demographics 
 PLA-Ex 
(n = 16) 
CHO-Ex 
(n = 16) 
t-test P value 












BMI (kg·m-2) 23.8 (3.0) 24.0 (2.6) 0.827 
 
 
Age (years) 29.0 (8.3) 28.5 (8.1) 0.864 
 
Training (h) 6.8 (3.1) 6.4 (2.5) 0.721 
 ሶܸO2max  
(ml·kg-1·min-1) 
55.7 (6.1) 60.9 (5.6) 0.017 
 






Table 3. Leukocyte responses to exercise 
 Pre-Ex Post-Ex 1 h Post-
Ex 
ANOVA main effects 
(group; time; trial × time) 
 
Leukocyte count 
(×109.l-1)        Ex-PLA 







10.4 (2.9)  
7.1 (1.3) aa 
 
 
10.2 (2.7)  
6.2 (0.6) aa 
 
 
0.313 ; <0.001 ; <0.001 
 
Neutrophil count 
(×109.l-1)         Ex-PLA 





7.6 (2.6)  
4.7 (1.2) aa 
 
7.9 (2.1)  
4.1 (0.8) aa 
 
0.005 ; <0.001  ; <0.001   
 
Lymphocyte count 
(×109.l-1)      Ex-PLA 
  Ex-CHO  
 






1.3 (0.5)  
1.4 (0.4) 
 
0.830 ; <0.001  ; 0.037   
 
N:L ratio 
          Ex-PLA 





4.9 (2.7)  
2.9 (0.9) 
 
6.5 (2.3)  
3.2 (1.2) aa 
 
0.053 ; <0.001  ; <0.001   
 
N:L ratio: Neutrophil-to-Lymphocyte ratio. Values are mean (SD); 
Post hoc (between groups): Significantly different to Ex-PLA a (P <0.05), aa (P <0.01). Post hoc results 









Table 4. Glucose and stress hormone responses to exercise 
 Pre-Ex Post-Ex 1 h Post-Ex ANOVA main effects 
(group; time; trial × time) 
     
Plasma Glucose   (mmol.l-1)  
   Ex-PLA 





4.2 (0.6)  
5.9 (0.9) aa 
 
3.8 (0.9) 
5.1 (1.1) aa 
 
0.002 ; 0.007 ; <0.001 
 
Cortisol (nmol.l-1)         
   Ex-PLA 






431 (218)  
259 (98) a 
 
398 (175)  
269 (81) a 
 
0.263 ; 0.037 ; 0.001 
 
Adrenaline   (nmol.l-1)         
   Ex-PLA 












0.961 ; 0.002  ; 0.857   
     
Noradrenaline (nmol.l-1)    
   Ex-PLA 





4.71 (2.02)  
4.98 (1.19) 
 
3.30 (1.19)  
3.18 (0.77)  
0.949 ; <0.001  ; 0.701   
 
Values are mean (SD); 
Post hoc (between groups): Significantly different to Ex-PLA a (P <0.05), aa (P <0.01). Post hoc results 































Figure 1. CHS response to DPCP elicitation 28 d after sensitisation: Summed increase in skin-fold 
thickness (left panel, values are mean ± SD) and full dose-series response (right panel, values are mean ± 
SEM), 48 h post elicitation.   
#note: Responses were also compared to 16 resting control (CON) subjects from Diment et al. [20] for additional 
comparison with a resting non-exercise condition (n =  16, 120 minutes of seated rest). 
* Indicates significantly different to CON (P <  0.05). There were no differences between Ex-PLA and Ex-CHO 
Figure 2. CHS response to DPCP elicitation 28 d after sensitisation: Summed increase in erythema (left 
panel, values are mean ± SD) and full dose-series response (right panel, values are mean ± SEM), 48 h 
post elicitation.   
#note: Responses were also compared to 16 resting control (CON) subjects from Diment et al. [20] for additional 
comparison with a resting non-exercise condition (n =  16, 120 minutes of seated rest). 
* Indicates significantly different to CON (P  <  0.05). There were no differences between Ex-PLA and Ex-CHO 
